Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 2
1999 1
2001 2
2003 3
2004 1
2006 3
2007 1
2008 1
2009 2
2010 3
2012 1
2013 4
2014 4
2015 15
2016 24
2017 23
2018 23
2019 28
2020 30
2021 33
2022 54
2023 62
2024 60
2025 74
2026 41

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

458 results

Results by year

Filters applied: . Clear all
Page 1
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Kronenberg F, et al. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. Eur Heart J. 2022. PMID: 36036785 Free PMC article.
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and …
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) i …
Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis.
Arsenault BJ, Loganath K, Girard A, Botezatu S, Zheng KH, Tzolos E, Abdoun K, Tastet L, Capoulade R, Côté N, Craig N, Chan KL, Tam JW, Teo KK, Couture C, Clavel MA, Mathieu P, Thériault S, Stroes ESG, Newby DE, Tsimikas S, Pibarot P, Dweck MR. Arsenault BJ, et al. JAMA Cardiol. 2024 Sep 1;9(9):835-842. doi: 10.1001/jamacardio.2024.1882. JAMA Cardiol. 2024. PMID: 39018080 Free PMC article.
OBJECTIVE: To determine the association between plasma lipoprotein(a) concentrations and hemodynamic progression in patients with aortic stenosis. ...Lowering plasma lipoprotein(a) concentrations warrants further investigation in the prev …
OBJECTIVE: To determine the association between plasma lipoprotein(a) concentrations and hemodynamic progression in patients w …
Lipoprotein(a) and cardiovascular disease.
Nordestgaard BG, Langsted A. Nordestgaard BG, et al. Lancet. 2024 Sep 28;404(10459):1255-1264. doi: 10.1016/S0140-6736(24)01308-4. Epub 2024 Sep 12. Lancet. 2024. PMID: 39278229 Review.
One in five people are at high risk for atherosclerotic cardiovascular disease and aortic valve stenosis due to high lipoprotein(a). Lipoprotein(a) concentrations are lowest in people from east Asia, Europe, and southeast Asia, int …
One in five people are at high risk for atherosclerotic cardiovascular disease and aortic valve stenosis due to high …
Lipoprotein(a) and aortic stenosis: Practical insights.
Dimitriadis K, Kyriakoulis KG, Pyrpyris N, Beneki E, Kamperidis V, Kollias A, Cenko E, Aznaouridis K, Aggeli K, Tsioufis K. Dimitriadis K, et al. Nutr Metab Cardiovasc Dis. 2025 Oct;35(10):104124. doi: 10.1016/j.numecd.2025.104124. Epub 2025 May 7. Nutr Metab Cardiovasc Dis. 2025. PMID: 40425406 Free article. Review.
DATA SYNTHESIS: Lp(a) is significantly involved in the pathogenesis of aortic stenosis (AS), with the interplay between AS and Lp(a) being documented in observational studies and a causal association being proposed based on genetic studies. ...CONCLUSION: Increased …
DATA SYNTHESIS: Lp(a) is significantly involved in the pathogenesis of aortic stenosis (AS), with the interplay between AS and …
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.
Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L. Tsimikas S, et al. J Am Coll Cardiol. 2018 Jan 16;71(2):177-192. doi: 10.1016/j.jacc.2017.11.014. J Am Coll Cardiol. 2018. PMID: 29325642 Free PMC article. Review.
Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). ...
Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal media …
Lipoprotein(a) and aortic stenosis.
Chan KL. Chan KL. Heart. 2022 Jan;108(1):9-10. doi: 10.1136/heartjnl-2021-320173. Epub 2021 Oct 5. Heart. 2022. PMID: 34611044 No abstract available.
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option.
Maloberti A, Fabbri S, Colombo V, Gualini E, Monticelli M, Daus F, Busti A, Galasso M, De Censi L, Algeri M, Merlini PA, Giannattasio C. Maloberti A, et al. Int J Mol Sci. 2022 Dec 22;24(1):170. doi: 10.3390/ijms24010170. Int J Mol Sci. 2022. PMID: 36613613 Free PMC article. Review.
Recently, new aspects have been identified, such as its association with aortic stenosis. Although till recent years it has been considered an unmodifiable risk factor, specific drugs have been developed with a strong efficacy in reducing the circulating levels of L …
Recently, new aspects have been identified, such as its association with aortic stenosis. Although till recent years it has be …
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
Duarte Lau F, Giugliano RP. Duarte Lau F, et al. JAMA Cardiol. 2022 Jul 1;7(7):760-769. doi: 10.1001/jamacardio.2022.0987. JAMA Cardiol. 2022. PMID: 35583875 Review.
OBSERVATIONS: Compelling evidence from pathophysiological, observational, and genetic studies suggest a potentially causal association between high Lp(a) levels, atherosclerotic cardiovascular disease, and calcific aortic valve stenosis. Additional evidence h …
OBSERVATIONS: Compelling evidence from pathophysiological, observational, and genetic studies suggest a potentially causal association betwe …
A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
Tsimikas S. Tsimikas S. J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042. J Am Coll Cardiol. 2017. PMID: 28183512 Free article. Review.
Evidence that elevated lipoprotein(a) (Lp[a]) levels contribute to cardiovascular disease (CVD) and calcific aortic valve stenosis (CAVS) is substantial. ...
Evidence that elevated lipoprotein(a) (Lp[a]) levels contribute to cardiovascular disease (CVD) and calcific aortic …
Lipoprotein(a) as Orchestrator of Calcific Aortic Valve Stenosis.
Schnitzler JG, Ali L, Groenen AG, Kaiser Y, Kroon J. Schnitzler JG, et al. Biomolecules. 2019 Nov 21;9(12):760. doi: 10.3390/biom9120760. Biomolecules. 2019. PMID: 31766423 Free PMC article. Review.
Aortic valve stenosis (AVS) is the most prevalent valvular heart disease in the Western World with exponentially increased incidence with age. ...The only treatment modality so far is surgical or transcatheter aortic valve replacement (AVR). …
Aortic valve stenosis (AVS) is the most prevalent valvular heart disease in the Western World with exponentially increa …
458 results